Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
11/12/2024 | $45.00 → $50.00 | Buy | Maxim Group |
9/18/2024 | $45.00 | Buy | Maxim Group |
2/22/2023 | $3.00 | Outperform | Northland Capital |
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
8-K - Nutex Health, Inc. (0001479681) (Filer)
10-Q - Nutex Health, Inc. (0001479681) (Filer)
8-K - Nutex Health, Inc. (0001479681) (Filer)
HOUSTON, April 22, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Scott J. Saunders, and Kelvin Spears, MD, to its Board of Directors. They replace John Waters, who recently passed away, and Dr. Daniel Stites, who fulfilled his one-year term Board commitment. The Board has determined that Mr. Saunders satisfies the current independent director standards established by the rules of The Nasdaq Stock Market. Mr. Saunders will s
HOUSTON, Sept. 5, 2023 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 8 states and primary care-centric, risk-bearing physician networks, today announced the appointment of Joshua DeTillio as the Company's Chief Operating Officer effective on or about October 2, 2023. Mr. DeTillio is an experienced healthcare leader with over 20 years of hospital experience and 12 years as a CEO in investor-owned, publicly traded companies. He has demonstrated success in collaborating with and leading boards and physicians to drive growth, improve c
HOUSTON, June 10, 2022 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, today announced the appointment of Jon Bates as the Company's Chief Financial Officer effective on or about June 30, 2022. On May 3, 2022, Michael Bowen notified the company that he intends to retire as Chief Financial Officer of the Company. In connection with Mr. Bowen's retirement, the Company's Board formed a search committee. On June 8, 2022, the Company announced the appointme
Maxim Group reiterated coverage of Nutex Health with a rating of Buy and set a new price target of $50.00 from $45.00 previously
Maxim Group initiated coverage of Nutex Health with a rating of Buy and set a new price target of $45.00
Northland Capital initiated coverage of Nutex Health with a rating of Outperform and set a new price target of $3.00
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
4 - Nutex Health, Inc. (0001479681) (Issuer)
HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691722&tp_key=bfd69ce
HOUSTON, Nov. 1, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1681991&tp_key=79ea06
HOUSTON, Aug. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in 9 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the second quarter ended June 30, 2024 after the close of the stock market on Thursday, August 8, 2024. The Company will discuss those results on a conference call on Friday, August 9, 2024 at 10:00 am ET. Participant Dial-In Numbers: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1681991&tp_key=79ea06250d
SC 13G/A - Nutex Health, Inc. (0001479681) (Subject)
SC 13G - Nutex Health, Inc. (0001479681) (Subject)
SC 13D - Nutex Health, Inc. (0001479681) (Subject)
Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today announced a 1-for-10 reverse stock split of its common stock effective with the market opening on Wednesday, July 3, 2024. The reverse stock split will take legal effect at 11:59pm Eastern Time on July 2, 2024, and the Company's common stock will open for trading on The Nasdaq Capital Market on July 3, 2024 on a post-split basis, under the existing ticker symbol "NUTX" but with new CUSIP number 67079U306. The reverse stock split is part of the Company's plan to regain compliance with the minimum bid price requirement for the continued listing on The Nasdaq Capital Market.
Nutex Health a physician-led, technology-enabled integrated healthcare delivery system comprised of 21 state-of-the-art micro hospitals in nine states and primary care-centric, risk-bearing physician networks, announced that during its annual shareholder meeting yesterday, it obtained approval from its shareholders to effect a reverse stock split of between 1-for-2 to 1-for-16.
- SEC Filing
TOTAL REVENUE OF $222.3 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $178.0 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 25%HOSPITAL DIVISION VISITS OF 122,944 FOR THE FIRST NINE MONTHS OF 2024 VS. VISITS OF 102,798 FOR THE SAME PERIOD IN 2023, AN INCREASE OF 20%HOSPITAL DIVISION OPERATING INCOME OF $54.7 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $21.1 MILLION FOR THE SAME PERIOD IN 2023, AN INCREASE OF 159%NET CASH FROM OPERATING ACTIVITIES OF $23.1 MILLION FOR THE FIRST NINE MONTHS OF 2024COMPANY CONTINUES ITS FOCUS ON INCREASING CASH FLOWHOUSTON, Nov. 7, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthca
HOUSTON, Nov. 5, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1691722&tp_key=bfd69ce
HOUSTON, Nov. 1, 2024 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), a physician-led, integrated healthcare delivery system comprised of 22 state-of-the-art micro hospitals in 10 states and primary care-centric, risk-bearing physician networks, today announced that it will release financial results for the third quarter ended September 30, 2024 after the close of the stock market on Thursday, November 7, 2024. The Company will discuss those results on a conference call on Friday, November 8, 2024, at 10:30 am ET. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant webcast: https://viavid.webcasts.com/starthere.jsp?ei=1681991&tp_key=79ea06